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Alzheimer’s disease (AD) is a neurodegenerative disorder with clinical manifestations of
progressive memory decline and loss of executive function and language. AD affects
an estimated 5.3 million Americans alone and is the most common form of age-related
dementia with a rapidly growing prevalence among the aging population—those 65 years
of age or older. AD is characterized by accumulation of aggregated amyloid-beta (Aβ)
in the brain, which leads to one of the pathological hallmarks of AD—Aβ plaques. As a
result, Aβ plaques have been extensively studied after being first described over a century ago. Advances in brain imaging and quantitative measures of Aβ in biological fluids
have yielded insight into the time course of plaque development decades before and
after AD symptom onset. However, despite the fundamental role of Aβ plaques in AD,
in vivo measures of individual plaque growth, growth distribution, and dynamics are still
lacking. To address this question, we combined stable isotope labeling kinetics (SILK)
and nanoscale secondary ion mass spectrometry (NanoSIMS) imaging in an approach
termed SILK–SIMS to resolve plaque dynamics in three human AD brains. In human AD
brain, plaques exhibit incorporation of a stable isotope tracer. Tracer enrichment was
highly variable between plaques and the spatial distribution asymmetric with both quiescent and active nanometer sub-regions of tracer incorporation. These data reveal that Aβ
plaques are dynamic structures with deposition rates over days indicating a highly active
process. Here, we report the first, direct quantitative measures of in vivo deposition into
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plaques in human AD brain. Our SILK–SIMS studies will provide invaluable information
on plaque dynamics in the normal and diseased brain and offer many new avenues for
investigation into pathological mechanisms of the disease, with implications for therapeutic development.
Keywords: Alzheimer’s disease, Aβ plaques, plaque dynamics, stable isotope tracer, SILK–SIMS

are lacking due to analytical challenges and limitations. Previous
human in vivo studies (22, 25, 35) relied on CSF and plasma,
which are indirect measures of the brain compartment and do
not directly measure plaques. PET imaging of human brain is an
average measure of amyloid pathology over ~1 cm, which does
not measure individual amyloid plaques, and amyloid tracers
bind only a subset of aggregated Aβ (36). Interpretation of PET
results is limited because amyloid binding agents measure binding sites and not necessarily the true amount of amyloid plaques.
Fluorescence-based assessments using multi-photon imaging of
over-expression models, which do not fully replicate the human
disease (37–39), encounter limitations resulting from specificity
of dyes, decreased sensitivity due to tissue autofluorescence, and
the inability to distinguish new versus previously existing Aβ or
other proteins found deposited into plaques (40). As individual
plaque dynamics have not been directly measured in humans, we
therefore sought to measure the in vivo incorporation of protein
into amyloid plaques to resolve whether plaques are stable or
dynamic structures in the human AD brain.
Stable isotope labeling kinetics (SILK) was developed to determine protein production and clearance by administering a stable
isotope labeled precursor in vivo and sampling during and after
labeling (41). The development of SILK allowed quantitation of
protein turnover in humans, providing a direct readout of changes
underlying pathophysiology of disease and pharmacodynamics
of therapeutics (22, 24, 42). However, SILK performed from CSF
or plasma does not convey localization of labeled biomolecules in
tissue. Nanoscale secondary ion mass spectrometry (NanoSIMS)
allows both imaging and measurement of stable isotopes at
high spatial resolution (50–100 nm or <1 μm3) (43, 44). While
NanoSIMS has been applied to the study of AD (45, 46), it has
not been used in combination with SILK for the measurement of
in vivo protein translation in cells or deposition into plaques in
normal or diseased brain. Here, we coupled SILK to NanoSIMS
in a method termed SILK–SIMS to directly measure and image
the distribution and rate of protein deposition (a proxy for growth
taking into account area) into individual plaques at the nanometer level (44, 47–49). Our aim was to measure the stability or
growth of individual amyloid plaques in AD animal models and
in the human brain.
Initial SILK–SIMS experiments in a mouse model of AD demonstrated in vivo detection of the stable isotope tracer 13C6-leucine
in native Aβ plaques. Further, plaques incorporated more of the
tracer via protein deposition compared to protein translation in
the surrounding brain parenchyma, but less than neurons. In
human AD brain, we found 13C enrichment in multiple diffuse
and dense-core plaques in both the frontal lobe and precuneus.
13
C enrichment was highly variable and asymmetric between
plaques with both quiescent and active nanometer sub-regions

INTRODUCTION
Alzheimer’s disease (AD) is a devastating neurodegenerative
disorder characterized by progressive cognitive and functional
decline and is the most common form of age-related dementia
(1, 2). The incidence of AD-related death and disability is rapidly
growing in persons 65 years of age or older whose risk of developing the disease doubles every 5 years (3); currently, an estimated
5.3 million Americans are affected (4). Amyloid-beta (Aβ), a
38–43 amino acid peptide derived from the proteolytic cleavage of
the amyloid precursor protein, is implicated as a pathogenic species in AD (5–10). Abnormal accumulation and aggregation of Aβ
in the cerebral extracellular space result in one of the pathological
hallmarks of AD—amyloid plaques. As a result, the onset and rate
of amyloidosis has been intensively studied over the past several
decades. Although older individuals may have extensive Aβ deposition without clinical signs of dementia (11–14), there is a strong
association of amyloid plaques with AD dementia. Longitudinal
measures of amyloid pathology have shown increases in amyloid
deposition 15–20 years prior to dementia onset (15) in early
onset, familial AD and predict future cognitive decline (16–20).
As amyloid pathology increases in vivo, a concomitant decline
in cerebrospinal fluid (CSF) Aβ42 occurs (21). More recent studies in the production and clearance of Aβ in CSF (22) demonstrate that the clearance of Aβ42 is decreased in AD. Intriguingly,
with the onset of amyloidosis, only the Aβ42 proteoform (23, 24)
demonstrated faster turnover kinetics attributed to rapid deposition into plaques—for ~50% of all Aβ42 produced (22). Further,
there was a positive correlation between increased Aβ42 turnover
kinetics and rate of amyloidosis measured by PET (22). In plasma,
the altered Aβ42 turnover kinetics and lower Aβ42/40 ratio with
amyloidosis is also present albeit to a lesser extent (25). These
data suggest that alterations in Aβ concentrations and kinetics
are strongly associated with amyloidosis reflecting deposition of
Aβ into plaques.
Longitudinal PET studies demonstrate that amyloid plaque
pathology increases slowly and plateaus with the clinical presentation of dementia (15, 20, 26–29). The slow accumulation of
amyloid tracer binding over decades before clinical presentation
of dementia has been suggestive of stability in plaque accumulation. The plateau of amyloid tracer binding may indicate that
amyloid pathology reaches dynamic equilibrium or quiescence
globally at the clinical stage of dementia. Similarly, several animal
model studies of plaques have demonstrated that plaques grow,
typically at earlier ages (30–32), to a stable size (32–34), but that
plaques may be in equilibrium with their environment if continual deposition is assumed (33).
However, despite the relevance of amyloid plaques in AD,
measures of in vivo growth and distribution of human plaques
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pentobarbital sodium and sacrificed by decapitation. Brains were
removed and placed in 10% neutral-buffer formalin (Catalog
#15740-01, EMS, Hatfield, PA, USA). Pieces of mouse brain were
washed into NaHCa and incubated overnight at 4°C. The following morning, samples were stained with 1% osmium/NaHCa for
1 h, washed four times over 1 h, and then en bloc stained with
1% uranyl acetate/H2O for 1 h in the dark. Samples were rinsed
with three exchanges of water, 10 min each, and then processed
for LR White embedding as described above with the addition of
being gold-coated once on the Si wafer. Serial adjacent sections
were placed on glass microscope slides for toluidine blue staining
for light microscopy.

of tracer incorporation. These data reveal that human Aβ plaques
are dynamic structures and suggest that they have growth or
turnover rates that can be directly quantified in AD brain. Our
results provide the first, direct measures of in vivo plaque dynamics in human AD brain. We predict that SILK–SIMS will provide a
precise understanding of protein deposition into amyloid plaques
in human AD brain and other CNS disturbances characterized
by protein aggregation.

MATERIALS AND METHODS
Cell Culture

B-cell hybridoma line (produced in-house by Holtzman Lab,
Washington University) was grown for 5 days in leucine-free
media that was supplemented with either 12C6-leucine or 13C6leucine at 26 mg/L and mixed at the appropriate percentage
of heavy isotope-containing media with 2% FBS. Cells were
harvested and spun at 1,000 rpm for 5 min at room temperature
(RT). Cell pellets were resuspended in 4°C Ringers wash solution
for 5 min, spun, and then fixed with 4% paraformaldehyde in
100 mM NaCl, 30 mM HEPES, 2 mM CaCl2, pH 7.2 (NaHCa)
for 2 h. This was followed by three rinses of NaHCa at RT and
overnight incubation at 4°C in NaHCa. Centrifugation was
used throughout the following steps in order to re-concentrate
the cells to a pellet. The following morning, pellets were placed
into ddH2O and then infiltrated with LR White Embedding
Media (Catalog #14383, EMS, Hatfield, PA) using the manufacturer’s published protocol with minor modification. Partial
dehydration was accomplished by using 20% EtOH 15 min,
40% EtOH 15 min, 50% EtOH 15 min, 70% EtOH 15 min, 85%
EtOH 10 min, followed by 1 h in a 2:1 LR White to 85% EtOH.
Sections of LR White embedded samples were cut on a Leica UC7
Ultramicrotome using a diamond knife. 200 nm and 400 nm
sections were picked up with a perfect loop, placed on top of a
polished silicon (Si) wafer (Catalog #534, University Wafer Inc.,
South Boston, MA, USA), and let air dry on a 35°C hot plate.

APP/PS1 Plasma Leucine

Mouse whole blood was spun at 1,000 × g for 10 min, and the
plasma (supernatant) was removed. Plasma proteins were
precipitated with ice-cold acetone followed by de-lipidation
with hexane, and the aqueous fraction was dried in vacuo (51).
1:1N-Methyl-N-tert-butyldimethylsilyltrifluoroacetamide/
acetonitrile was added, and samples were incubated at 70°C for
30 min. Duplicate 1 µL injections were made into an Agilent 5973
MSD mass spectrometer using a 30 µm × 0.25 mm DB-5MS
column (Agilent Technologies). Electron impact ionization
and selected ion monitoring were used to measure endogenous
unlabeled leucine at m/z 200 (molecular ion minus C-1 as CO2tert-butyldimethylsilyl; CO2-tBDMS), and 13C6-leucine (tracer)
was measured at m/z 205 as an m + 5 ion. The tracer-to-tracee
ratio (TTR) was taken as the m + 5/m + 0 peak area ratio of
the biological sample minus the m + 5/m + 0 ratio of a natural
abundance leucine sample. The molar fraction of labeled leucine
was calculated as: MFL = TTR/(1 + TTR).

Human Tissue

Clinically and neuropathologically well-characterized human
brain tissue samples were obtained from the Charles F. and
Joanne Knight Alzheimer’s Disease Research Center (Knight
ADRC), Washington University School of Medicine, Saint
Louis, Missouri. At the time of death, written informed consent
in accordance with the Declaration of Helsinki was obtained
from the next-of-kin in accordance with the protocol approved
by the Washington University Human Studies Committee and
the General Clinical Research Center Advisory Committee.
Cognitive status at expiration was determined using a validated
retrospective post-mortem interview with an informant to
establish the clinical dementia rating (CDR) (52). We used frozen
tissue from the frontal lobe (Brodmann areas 8/9) of Pt2 with
mild AD dementia (CDR 1, age at death = 88 years; post-mortem
interval = 15 h; post-labeling interval (delta) = 8 days; Table 1).
The right cerebral hemisphere was coronally sliced at 1 cm intervals and snap frozen by contact with pre-cooled Teflon®-coated
aluminum plates, and temperature equilibrated by immersion
into liquid nitrogen vapor in a cryo-vessel. Following freezing,
tissues were placed in Ziploc® storage bags and stored in freezer
at −80°C. Participants 2 and 3 were given the stable isotope tracer
13
C6-leucine as part of previous SILK studies (22, 35). These AD
participants had made previous arrangements for brain donation
to Washington University.

Animals

All animal procedures were conducted in accordance with
the animal protocol approved by the Washington University
Animal Studies Committee and are consistent with the National
Institutes of Health (NIH) guidelines for the care and use of
animals. Two male double transgenic mice expressing chimeric
mouse/human amyloid precursor protein (Mo/HuAPP695swe)
and a mutant human presenilin 1 (PS1-dE9) both directed to
CNS neurons (stock 34832-JAX) (50) were kindly provided
by Dr. Timothy Miller. Animals were given leucine-free chow
(Catalog #1831936, Test Diet, St. Louis, MO, USA) with 5 mg/mL
12
C6-leucine added to 2% sucrose-containing drinking water to
control leucine intake for a one-week acclimation period. After
the 1-week acclimation period, animals were given 5 mg/mL
13
C6- or 12C6-leucine orally via 2% sucrose drinking water, averaging 36 mL of H2O/week. Animals were 4 months old at the time
of labeling (pre-plaque pathology) and 6.5 months old at the end
of labeling (onset of plaque pathology). Following the end of the
labeling paradigm, animals were anesthetized with 65 mg/kg
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TABLE 1 | Patient demographics for SILK-SIMS imaging of Aβ plaques.
Participant
1
2
3

Amyloid status PET-PiB

CDRa

AD dementia

MMSEa

Gender

Age

Δ Between labeling and DOE (days)

N/A
pos
pos

N/A
1
1

N/A
Mild
Mild

N/A
22
11

M
M
M

59
88
88

N/Ab
1,150 and 8c
1,648

Clinical autopsy provided a diagnosis of Alzheimer’s disease (AD) for all participants.
CDR, clinical dementia rating; MMSE, mini mental state exam; DOE, date of expiration.
a
CDR and MMSE as most recent.
b
This participant was not part of the SILK studies.
c
This participant was in two SILK studies and thus has two time lapses.

Formalin-fixed tissue from the frontal lobe, including the
cortical ribbon, of Pt1 (negative control, no labeling), Pt2
(delta = 8 days), and Pt3 (delta = 4.5 years) were post-fixed in 2%
osmium tetroxide in 0.1 M sodium cacodylate buffer for 1 h, en
bloc stained with 3% aqueous uranyl acetate for 1 h, dehydrated in
graded ethanols, and embeded in PolyBed 812 catalog #08792-1
(Polysciences, Hatfield, PA, USA). Blocks were polymerized at
80°C for 72 h. Tissue blocks were sectioned using a diamond
ultrathin section knife on a Reichert Ultra-Cut E ultramicrotome
at 300–500 nm. Sections were transferred to a single polished
Si wafer for SILK–SIMS analysis. Serial adjacent sections were
placed on glass microscope slides for toluidine blue staining for
light microscopy. The precuneus of Pt2 was prepared and embedded in LR White as described above for animal tissue along with
samples from the 10-week labeled APP/PS1 mouse (positive
control) and Pt1 (negative control). Serial adjacent sections were
placed on glass microscope slides for toluidine blue staining for
light microscopy.

deposition. PiB was prepared as previously described (53). PET
and MRI were performed as previously described (54).

NanoSIMS

Data were acquired on either a Cameca NanoSIMS 50 at
Washington University (cells and human tissue) or NanoSIMS
50 L at Brigham and Women’s Hospital (mouse tissue). Images of
the B-cell hybridoma used to calculate the 13C6-leucine standard
curve were acquired with a 50 µm primary beam raster for 15 min
at 1 ms/px and 65.5 s/plane (dwell time) for a total of 10 planes
(i.e., cycles) per mass (256 × 256 px). APP/PS1 mouse brain tissue
was acquired at a 17–60 µm raster for 11–87 min at 2 ms/px and
131 s/plane (dwell time) for a total of 5–40 cycles (i.e., planes)
per mass (256 × 256 px). For all APP/PS1 measurements, the
non-labeled cells (0%) were measured prior to the SILK–SIMS
data acquisition. The unlabeled cells and the natural abundance
of carbon-13 (55) were used for quantitation of normalized
ratios for mouse plaques and neuron. Plaque ROI outlines were
drawn based on plaque morphology and areas around the plaque
defined such they do not overlap or intersect with the predefined
plaque ROIs.
The human tissue was analyzed in three sets. In the first set
(frontal lobe), Pt1 (negative control) and Pt2 frontal lobe were
embedded in PolyBed 812 and pre-sputtered using the D1-1
aperture for 10 min followed by data acquisition at a raster size
between 35 and 50 µm raster with a D1-2 aperture. Data acquisition was 4 h at 5 ms/px and 327.68 s/plane (dwell time) for a
total of 40 planes (i.e., cycles) per mass (256 × 256 px). In the
second set (precuneus), Pt2 precuneus samples (embedded in
LR White; Figures S9 and S11 in Supplementary Material) were
pre-sputtered at 30 µm raster with a D1-1 aperture for 10 min followed by data acquisition at 25 µm raster with the D1-2 aperture.
Data acquisition was 2.5 h at 5 ms/px and 327.68 s/plane (dwell
time) for a total of 25 planes (i.e., cycles) per mass (256 × 256
px). Pt1, also embedded in LR White, was used as the negative
control in this experimental set. Finally, unlabeled AD tissue
(Pt1; in Supplementary Material) embedded in PolyBed812 was
acquired with a 45 µm raster for 11.6 h at 4 ms/px and 1,048.576 s/
plane (dwell time) for a total of 40 planes (i.e., cycles) per mass
(512 × 512 px). Pt3’s (in Supplementary Material) brain tissue
was acquired with a 55 µm raster for 18 h at 5 ms/px and 1,310 s/
plane (dwell time) for a total of 40 planes (i.e., cycles) per mass
(512 × 512 px). For all measurements, the non-labeled material
(Pt1) was measured prior to the SILK–SIMS data acquisition.
In this way, the negative control data were acquired first before

Light Microscopy

Toluidine blue stained sections were imaged with a Hamamatsu
NanoZoomer 2.0-HT System. Imaging was done to guide feature
identification and location for electron microscopy.

Electron Microscopy

Images of the tissue and reference points were taken with a field
emission scanning electron microscope (FE-SEM; QuantaTM 3D
FEG, FEI, Hillsboro, OR, USA) in order to document plaque locations and provide an absolute coordinate system for the tissue.
In-house coordinate transformation software was used to translate tissue regions-of-interest (ROIs) and reference points found
in the FE-SEM to the NanoSIMS instrument stage coordinate
plane for relocation of the same ROIs. Additional sections were
cut at 70–90 nm for transmission electron microscopy (JEOL
JEM-1400Plus) to image selected plaques to define ultrastructure.
Anti-Aβ antibody 82E1 (1:50; Aβ N-terminal epitope (1-16); IBLAmerica, Minneapolis, MN, USA) was used with goat anti-mouse
secondary antibody conjugated to 10 nm gold particles (1:15).

Magnetic Resonance Imaging (MRI)
and PET-PiB Imaging

Participants were labeled with the radiotracer N-methyl-2(4-methylaminophenyl)-6-hydroxybenzothiazole
(Pittsburgh
compound B, PiB) for human brain PET imaging of amyloid
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SILK data acquisition, and the electron multipliers were no longer
adjusted after negative control data were acquired.

overnight incubation at 4°C, IPs were eluted in neat formic acid
and dried in vacuo. Samples were resuspended in 50 mM TEABC
(Catalog #17902, Sigma, St. Louis, MO, USA), spiked with 15NAβ internal standard, and digested overnight with 0.25 ng/µL
Lys-N (Catalog #100965-1, Seikagaku Biobusiness Corp., Tokyo,
Japan) at 4°C.

NanoSIMS Data Analysis

Each analysis was performed in 24-h blocks with measurements
on a SiC standard of known isotopic composition to assess
instrument stability followed by measurements on an unlabeled
control prior to SILK–SIMS data acquisition. Raw image data
were imported into the L’Image image processing software (Larry
Nittler, Carnegie Institution of Washington) to produce quantitative ratio images of heavy and light isotopes and determine where
isotopic anomalies were located. Images were automatically
segmented into 10 × 10 pixel ROIs using L’image, and the heavy/
light isotopic ratios were calculated from the summed ion counts
within each ROI. The fractional uncertainty, ƒ, of each ROI ratio
heavy/light isotope ratios in each region-of-interest (ROI) was
calculated in Excel as the sum in quadrature of the standard
deviation of the average ratios measured for non-labeled material, σStd, and the Poisson errors, σROI, of the ROI itself, as given
by the equation
2

 σStd   σROI 
f = 
 +

 RStd   RROI 

2

Mass Spectrometry

Samples were resuspended in 1% FA/10% ACN (v/v) with 20 nM
BSA digest (Catalog #1863078, Pierce, Rockford, IL, USA).
Samples were analyzed in triplicate by nanoLC-MS/MS on an
LTQ-Orbitrap Fusion (Thermo Fisher Scientific) in positive ion
mode. Separations were performed using an online NanoAcquity
UPLC (Waters, Milford, MA, USA) using an ACQUITY UPLC
HSS T3 (360 µm OD × 75 µm ID) column packed with 10 cm
C18 (1.8 µm, 100 Å, Waters) at 300 nL/min and heated to 65°C.
Mobile phases were 0.1% FA in water (A) and 0.1% FA in ACN
(B). Samples were eluted from the column with the gradient
starting at 12% B, which was ramped to 32% B over 10 min and
further increased to 90% B over 5 min and held for 1 min, before
re-equilibration to 12% B over 2 min. Total run time, including
column equilibration, sample loading, and analysis, was 30 min.
The mass spectrometer was operated in targeted MS2 mode.
MS2 spectra were acquired in the Orbitrap (30,000 at m/z 400)
in centroid mode using XCalibur, version 4.0 (Thermo Fisher
Scientific). Ion injection times for the targeted MS2 scans for
labeled and unlabeled samples, respectively (in ms) were: Aβ
mid-domain (54, 1080), Aβ40 (54, 540), and Aβ42 (54, 1080). The
Orbitrap automatic gain control targets were set to 5 × 105 for all
proteoforms except Aβ42, which was set to 1 × 106. The targeted
precursor ions were sequentially isolated in the quadrupole and
fragmented in the Orbitrap using HCD (isolation width 1.6 Da,
normalized collision energy 25%, activation Q 0.250, and activation time 10 ms). The general mass spectrometric conditions were
as follows: spray voltage 2.2 kV, 60% S-lens, and ion transfer tube
temperature 275°C.

(1)

where RStd is the average ratio of repeated measurements on
unlabeled tissue, and RROI is the ratio calculated from summing
the counts of every pixel contained within the individually
defined ROI. This uncertainty represents the entire experimental
precision and accuracy, including: counting statistics, matrix
effects, systematic error, instrumental tuning, and differences
between standards and samples. From this uncertainty, the
amount, significance, and location of heavy isotopic labeling
can be quantitatively determined. Those ROIs with heavy/light
isotope ratios greater than or equal to the μ + 2σ value of the
unlabeled sample were analyzed by a one-sample t-test. Two SDs
from the mean (2σ) was chosen to ensure high confidence in
isotope enrichment (i.e., 95%) prior to the one-sample t-test; by
analogy in the field of Physics, a minimum 5σ effect is required
for statistical confidence. Each t-value of the resulting t-tests
was corrected for multiple testing with a FDR of 0.01 using the
Benjamini-Hochberg method (56). Those ROIs which remained
significant after correcting for multiple comparisons remain
outlined in the images.

Mass Spectrometry Data Analysis

Data (.raw files) were imported into a Skyline template containing the Lys-N C-terminal peptides of Aβ38, 40, 42, and the middomain. Retention time alignment was based on the 15N internal
standard. The sum of all transitions (b ions monitored for each
parent peptide) for unlabeled and 13C6-leucine labeled Aβ peptides were exported from Skyline to Excel. The ratios of labeled/
unlabeled of each replicate (triplicate injections) for Pt2 sample
were taken followed by isotopic background subtraction of the
mean ratio of an unlabeled participant to give the TTR minus
background for each replicate injection. Next, the background
subtracted TTRs were used to calculate the mean and SD (i.e.,
the mean of the area ratios) of enrichment for each Aβ peptide.

Aβ Extraction

1 g of frontal lobe tissue was homogenized in ice-cold 1X PBS
with 0.05% CHAPS and centrifuged at 17,000 × g for 30 min at
4°C as previously described (57). The supernatant was spun for
1 h at 100,000 × g at 4°C, and the resulting pellet was solubilized
in 5 M guanidine overnight at 4°C with rotation. Next, samples
were spun for 20 min at 17,000 × g at 4°C, and the supernatant
was diluted 1:10 in 1X PBS in BSA-block tubes as previously
described (57). Samples were immunoprecipitated (IP) with 50
μL of HJ5.1 anti-Aβ antibody [mid-domain epitope (17–28)]
coupled Dynabeads (Catalog #14311D, Invitrogen, Carlsbad,
CA, USA) made following the manufacturer’s instructions. After
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NanoSIMS image files (.im) and L’Image saved session (.sav) files
are available upon request from corresponding authors. Excel
data analysis files for human NanoSIMS images can be found in
the Supplementary Material.
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FIGURE 1 | SILK-SIMS dose response curve for 13C6-leucine enrichment. B-cell hybridoma cells were labeled with increasing percentages of 13C6-leucine. The
standard curve demonstrates a monotonic relationship between detected 13C14N/12C14N and the percent 13C6-leucine enrichment in cell media. Red line represents
the mean of 13C14N/12C14N ± SD of the regions-of-interest outlined in (Figure S3 in Supplementary Material). The blue line represents the normalized mean
13 14
C N/12C14N ± SD. Each standard curve point was normalized (Equation 4 in Supplementary Material) to the ratio of natural abundance 13C and unlabeled cells
(0%). The normalized SD was calculated as the sum in quadrature of the SD of the average ratios measured for non-labeled cells (0%) and the Poisson errors of the
feature itself (Equation 5 in Supplementary Material). Note the expected intercept at ~1.1%. Inset: enlarged view of the three lowest points on the dose-response
curve. Enrichments as low as 1.25% were detectible above background. Dashed horizontal line represents natural abundance of 13C (1.1%).

RESULTS

incorporated substantially more tracer than the surrounding
parenchyma (neuron = 3.3% ± 0.05% vs. area 1 = 2.4% ± 0.03% vs.
area 2 = 2.4% ± 0.03%) and the plaque (Figure S5 in Supplementary
Material) in the 10-week labeled mouse. These results demonstrate that 13C6-leucine incorporation into Aβ plaques and other
features could be measured and is localized to protein deposition
(i.e., plaques) and protein translation (i.e., cells).

Quantification of 13C and In Vivo Labeling

To quantify carbon isotopes in biological material, we measured
carbon as negative ions of 12C, 13C, 12C14N, and 13C14N. Using a
B-cell hybridoma grown in leucine-free media supplemented
with increasing percentages of 13C6-leucine, we characterized the
signal response for 13C enrichment. Figure 1 demonstrates the
linearity of response of SILK–SIMS measurements to increasing
isotopic enrichment of 13C6-leucine in culture measured as the
ratio of 13C14N/12C14N, which produced improved image quality
and more accurate quantification (Figure S1–3 in Supplementary
Material). To determine whether 13C6-leucine enrichment could
be detected in vivo in native Aβ plaques, two individual APP/PS1
mice (3.5 months of age) were administered 13C6-leucine tracer
for 10 and 5 weeks (Figure 2A). The mouse labeled for 10 weeks
(Figure 2B) reached a 13C14N/12C14N ratio of 2.4% ± 0.03% in
plaque (expected unlabeled at 1.1% due to 13C natural abundance)
compared to brain parenchyma (2.2% ± 0.03%) in both Area 1
and Area 2 (Figure 2B; Figure S4 in Supplementary Material).
A plaque from the APP/PS1 mouse labeled for 5 weeks, followed
by a 5-week washout, remained enriched at 1.6% ± 0.02% relative to natural abundance (Figure 2C), and compared to adjacent
areas (1.4% ± 0.02%). Despite being labeled for half the amount
of time with an additional 5 weeks of tracer washout, the plaque
enrichment was approximately two-thirds of that measured in the
10-week labeled animal (1.6% ± 0.02% vs. 2.4% ± 0.03%). The
enrichment of plasma leucine measurements taken at the time of
collection was fourfold lower (72 vs. 16% isotopically labeled leucine in the 10-week vs. 5-week labeled mouse, Table 1). A neuron
Frontiers in Neurology | www.frontiersin.org

In Vivo Labeling and Quantification
of Human AD Plaques

The APP/PS1 mouse model (50) is an over-expression model of
APP mutations typically found in early onset, familial disease,
which accounts for <1% of AD cases (58) and does not replicate
all aspects of the human disease or human amyloid-plaques
(37–39). Further, despite intensive study of plaque dynamics in
animal models (30–34), little is known about individual plaque
dynamics in human AD brain. The demonstrated feasibility
of measuring 13C6-leucine incorporation in native Aβ plaques
from mouse brain (Figure 2) prompted us to investigate postmortem tissue from previous SILK study participants (22, 35).
Plaques from unlabeled AD participant tissue (Table 2; Figure
S6 in Supplementary Material) were similar to the natural
abundance of 13C as expected. In a previous SILK participant
(Pt3) (22), who had a post-labeling interval of 4.5 years (Figure
S7 in Supplementary Material), we were also unable to detect
13
C enrichment in the examined areas. In contrast, post-mortem
tissue from Pt2, who was labeled (35) and passed away 8 days
later due to an unrelated cause, had significant 13C enrichment
in amyloid plaques (Figure 3). Four diffuse plaques in the
6
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FIGURE 2 | Stable isotope incorporation within plaques of APP/PS1 mouse model of Alzheimer’s disease. (A) Labeling scheme to determine the feasibility of
detecting in vivo incorporation of stable isotope 13C in native Aβ plaques. (B,C) From left to right, 12C14N ion map, 13C14N ion map, 13C14N/12C14N ion map, and
normalized 13C14N/12C14N ratios of 10-week and 5-week labeled APP/PS1 mice, respectively (35 × 35 μm images; see, Figure S4 in Supplementary Material, for
region-of-interest (ROI) outlines based on plaque morphology and areas around the plaque defined such they do not overlap with plaque ROIs). Error bars
indicate ± SD in quadrature of the SD of the average ratios measured for non-labeled cells (0%) and the Poisson errors of the feature itself (Equation 5 in
Supplementary Material). Dashed horizontal line represents natural abundance of 13C (1.1%). Scale bar, 2 µm.

TABLE 2 | Plasma leucine in labeled APP/PS1 mice.
12

C6-Leucine peak area

13

C6-Leucine peak area

C/12C

TTR

Mol fraction labeled

Average Mol fraction labeled

13

10 week

4,579
4,601

11,793
11,845

258%
257%

258%
257%

72%
72%

72%

5 week

14,438
14,256

2,878
2,724

20%
19%

20%
19%

16%
16%

16%

Each sample was injected twice with excellent reproducibility.
TTR, tracer-to-tracee ratio.

area (Figures 3C,D; Figure S8 in Supplementary Material). To
confirm this result was not restricted to a single brain region, we
examined plaques in the precuneus (Figure S9 in Supplementary
Material). Of the two dense-core plaques imaged by SILK–SIMS
and verified by immunoelectron microscopy (Figure S10 in
Supplementary Material), only plaque 5 had 13C enrichment
within the plaque, the peri-plaque region (Figures S9A–F in
Supplementary Material), and up to 50 µm away (Figure S11 in
Supplementary Material). In contrast, plaque 6 had a low number of enriched regions, which appear part of the surrounding
brain parenchyma (Figures S9G–L in Supplementary Material)
rather than the plaque itself, suggesting a quiescent plaque. To

frontal lobe displayed puncta of 13C labeling intercalated in the
periphery and fibrillar interior (Figure 3C). Notably, not all
plaques demonstrated equivalent amounts of 13C incorporation
or the same number of enriched regions (max 13C = 1.26, 1.34,
1.49, and 1.20%, for plaques 1–4, respectively). Among plaques
with an equivalent number of enriched regions (e.g., plaques
2 and 3) 13C enrichment varied, suggesting differing rates of
13
C incorporation among “dynamic” plaques (Figures 3C,D).
Additionally, the number of areas with significant enrichment
drastically differed, indicating that plaque incorporation of 13C
is highly asymmetric and can be constrained to specific regions
or sub-regions; in the case of plaque 4, it is confined to a 3.0 µm2
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FIGURE 3 | In vivo stable isotope incorporation of 13C within plaques in the frontal lobe of clinically and pathologically confirmed Alzheimer’s disease brain.
(A) Primary question: are amyloid-β plaques dynamic structures able to incorporate the stable isotope tracer 13C6-leucine and can this be directly measured in the
human brain? (B) Traditional imaging of SILK Pt2 by T2-weighted magnetic resonance imaging (MRI) (upper) and by PET-PiB (lower) in a coronal view. Hippocampal
atrophy (red) in the MRI image is apparent along with prominent PiB binding in the PET image. SUVR, standardized uptake value ratio. (C) Four diffuse plaques in
the frontal lobe of SILK Pt2 and a dense core plaque from the frontal lobe of non-SILK Pt1 (Table 2). From left to right, scanning electron microscope (SEM) image
of the plaque (red box defines area imaged by SILK–SIMS), 12C14N ion map, 13C14N ion map, and 13C14N/12C14N ion map. (D) Summary scatter plot of all plaque
region-of-interest normalized ratios shown below. Horizontal bars represent plaque 13C14N/12C14N medians, and dashed horizontal line represents natural abundance
of 13C (1.1%). Scale bar for all SEM images, 40 µm. Scale bar for all SILK–SIMS images, 5 µm. SEM magnification and SILK–SIMS image raster, respectively: Plaque
1: 636X and 25 × 25 μm; Plaque 2: 1,024 and 35 × 35 μm; Plaque 3: 628X and 50 × 50 μm; Plaque 4: 628X and 45 × 45 μm; NegControl: 600X and 45 × 45 μm.

DISCUSSION

provide orthogonal validation of the presence of 13C6-leucine
Aβ proteoforms (23) in Pt2 brain, we used targeted nLC-MS/
MS. In Aβ from insoluble aggregates (57), we quantified 13C6leucine labeled Aβx-40, 42, and mid-domain peptides, which
were enriched at relative abundances of 0.112, 0.022, and 0.053%
above natural abundance, respectively, while Aβx-38 was not
detected as expected (Figure 4).
Frontiers in Neurology | www.frontiersin.org

In the current study, we utilized brain tissue from participants
enrolled in previous SILK studies (22, 35) for NanoSIMS imaging.
During the in vivo stable isotope labeling procedure (41) newly
synthesized proteins are labeled simultaneously. As a result, many
different features (e.g., plaques, parenchyma, and neurons) and
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FIGURE 4 | Continued
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FIGURE 4 | Targeted nLC-MS/MS of Aβ proteoforms from an insoluble fraction of SILK Pt2. Extracted ion chromatograms (XIC) are shown for (A) Aβ mid-domain,
(B) Aβx-40, and (C) Aβx-42 in Pt2 (8 day delta between labeling and expiration) of unlabeled Aβ and 13C6-leucine labeled (SILK), respectively. (D) The average of each
tracer-to-tracee ratio (TTR) from triplicate injections using targeted nLC-MS/MS after background subtraction from an unlabeled participant sample. The relative
quantitation of Aβ mid-domain, Aβx-40, and Aβx-42 provides additional evidence of 13C6-leucine present in the brain even after supposed label washout. Error bars
represent ± SD.

versus direct human pathophysiology. Multi-photon imaging has
the advantages of visualization of individual plaques over time in
the same animal non-destructively albeit at lower resolution limit
compared to SILK–SIMS. In contrast, SILK–SIMS is a destructive technique where the isotope profiles are obtained at the
expense of the molecular identities of the newly synthesized and
deposited biomolecules. This is particularly relevant as plaques
are heterogeneous structures containing other proteins, cellular
debris, and lipids (40), which may contribute to the 13C signal
seen in the SILK-SIMS images. As Aβ is the main constituent of
plaques, we validated 13C enrichment by nLC-MS/MS from the
same sample in an orthogonal manner. This orthogonal measure
can be applied to other proteins of interest (e.g., alpha-synuclein,
tau, and prion protein), or MALDI imaging (60, 61) may be used
in parallel to obtain molecular identities of plaque constituents
in situ, though at micrometer resolution.

kinetic processes (e.g., protein translation, transport, deposition, and clearance) in the brain can be imaged directly without
the reliance of analytical intermediaries or modifications such as
fluorescence. In the previous SILK studies, 13C6-leucine was used
as the tracer (41, 59). However, in SILK-SIMS, 13C is isotopically
diluted, decreasing sensitivity, due to the abundance of carbon
in mammalian tissues and the carbon-based embedding media.
As a result, we were only able to successfully detect 13C enrichment in one participant who had a post-labeling interval of eight
days. Yet, to the best of our knowledge, this represents the first
report of imaging of individual human amyloid plaques in vivo
dynamics at the nanometer scale not appreciable by previous
methods.

Human Aβ Plaques Are Dynamic
Structures

The incorporation of 13C6-leucine into plaques (i.e., protein
deposition) in a participant with clinical stage AD dementia suggests that plaques can be dynamic with activity over days even in
later stages of the disease. Notably, we were able to demonstrate
dynamic activity in both diffuse and dense-core plaques in
contrast to previous animal model studies (30–34), which were
restricted to imaging dense-core plaques due to the use of fluorescent plaque binding reagents Thioflavin S and Methoxy-04.
The “activity” of individual plaques can be highly variable as
demonstrated by varying isotope enrichment, suggesting differing rates of protein incorporation even among individual plaques
in the same brain region. A single plaque could simultaneously
demonstrate nanometer scale regions of dynamic incorporation
of the tracer as well as quiescence—highly asymmetric tracer
incorporation.
Plaque asymmetry was previously suggested (33) in a mouse
model of AD but was attributed to asymmetrical clearance. The
quiescence regions and sub-regions of individual plaques could
be interpreted as either asymmetric clearance or differential
nanometer scale deposition. However, not all plaques incorporated the tracer indicating a lack of protein deposition during the
same timeframe. Together, these results demonstrate that plaques
can be at both dynamic equilibrium and quiescence within a single participant even with dementia, at both the individual plaque
level and plaque nanometer sub-region level, despite PET studies
suggesting no net change (20, 26–29).

CONCLUSION AND OUTLOOK
The application of SILK–SIMS to future studies will allow
estimates of the rate and distribution of plaque deposition at
the nanometer level across human AD cohorts. The results will
provide a better understanding of the rate of AD pathophysiology and may have a significant impact on the development of
therapeutic strategies; for example, drugs targeting amyloid
plaque growth and resorption through a variety of mechanisms.
However, SILK–SIMS, unlike PET imaging, is currently limited
to post-mortem tissue. Biopsies are an alternative but are invasive
and only feasible with surgery to relieve other conditions such as
normal pressure hydrocephalus. Nonetheless, SILK–SIMS may
also be applied to measuring other proteinaceous deposits such
as Lewy bodies (alpha-synuclein), neurofibrillary tangles (tau),
and prion protein, which are characteristic of Parkinson’s disease,
frontotemporal dementia and AD, and Creutzfeldt–Jakob disease,
respectively. In general, the SILK–SIMS approach can be used to
visualize incorporation of new biomolecules at the nanometer
scale to measure growth and turnover to better understand physiology and pathophysiology of many disease states, neurological
and non-neurological.
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